论文部分内容阅读
目的观察阿嗪米特治疗糖尿病胃肠病的临床疗效。方法将糖尿病胃肠病患者110例依据不同的治疗方法分为观察组和对照组各55例。2组患者均给予生物合成人胰岛素注射液及精蛋白锌重组人胰岛素混合注射液治疗,观察组患者加用阿嗪米特治疗,对照组患者加用西沙比利治疗,比较2组患者的治疗效果、血糖指标及不良反应发生率。结果观察组患者的治疗总有效率为98.2%高于对照组的83.7%,差异有统计学意义(P<0.05)。2组患者的早餐后2h血糖水平比较差异无统计学意义(P>0.05)。观察组患者的糖化血红蛋白、空腹血糖均低于对照组,不良反应发生率为1.8%低于对照组的14.5%,差异均有统计学意义(P<0.05)。结论糖尿病胃肠病患者在常规胰岛素治疗的同时加用阿嗪米特的疗效显著,且不良反应少,值得临床推广和应用。
Objective To observe the clinical efficacy of azimit in the treatment of diabetic gastrointestinal disease. Methods 110 cases of diabetic patients with gastrointestinal disease were divided into observation group and control group according to different treatment methods in 55 cases. Two groups of patients were given biosynthesis of human insulin injection and recombinant protein injection of recombinant human insulin treatment, the observation group were treated with alzamine, the control group plus cisapride treatment, the treatment of two groups were compared Effect, blood sugar level and the incidence of adverse reactions. Results The total effective rate of observation group was 98.2% higher than 83.7% of control group, the difference was statistically significant (P <0.05). There was no significant difference in blood glucose level between the two groups 2h after breakfast (P> 0.05). The HbA1c and fasting blood glucose in the observation group were lower than those in the control group, the incidence of adverse reactions was 1.8% lower than that of the control group (14.5%), the differences were statistically significant (P <0.05). Conclusion The patients with diabetic gastrointestinal disease treated with conventional insulin at the same time with azathim has significant curative effect and less adverse reactions, which is worthy of clinical promotion and application.